^
Association details:
Biomarker:EGFR rearrangement
Cancer:Lung Cancer
Drug Class:EGFR inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

P89.01 - Clinical and Genomic Features of EGFR-KDD/EGFR Rearrangements of Chinese Lung Cancer Patients

Published date:
01/12/2021
Excerpt:
Some reports had shown that several types of EGFR rearrangements were sensitive to EGFR-TKI therapists, but EGFR rearrangements were also found in 4 EGFR-TKI resistance patients.